Skip to main content

LCD L39711: MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy

LCD L39711, MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy, is the Local Coverage Determination that Wisconsin Physicians Service Insurance Corporation applies to claims from 48 states (AK, AL, AR, AZ, CA, CO, CT, DE and others), effective 2026-06-25 and first in force 2024-09-22. The policy text runs 577 words, and its billing and coding article A59551 lists 2 ICD-10-CM codes that support medical necessity for 1 procedure code. 3 other contractor versions share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 2 covered ICD-10-CM codes: the same total as L39654 (Palmetto GBA, 2 codes, revised 2024-09-22) and the same total as L39678 (Noridian Healthcare Solutions, LLC, 2 codes, revised 2026-01-22).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Wisconsin Physicians Service Insurance Corporation
States and territories
48
AK AL AR AZ CA CO CT DE FL GA HI IA ID IL IN KS KY LA MA MD ME MI MO MS MT NC ND NE NH NJ NM NV OH OK OR PA RI SC SD TN TX UT VA VT WA WI WV WY
Revision effective
2026-06-25
Original effective
2024-09-22
Policy text
577 words
Covered ICD-10 codes (articles)
2

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L39711
ContractContractorTypeStates
05101Wisconsin Physicians Service Insurance CorporationMAC - Part AIA
05201Wisconsin Physicians Service Insurance CorporationMAC - Part AKS
05301Wisconsin Physicians Service Insurance CorporationMAC - Part AMO
05401Wisconsin Physicians Service Insurance CorporationMAC - Part ANE
05102Wisconsin Physicians Service Insurance CorporationMAC - Part BIA
05202Wisconsin Physicians Service Insurance CorporationMAC - Part BKS
05302Wisconsin Physicians Service Insurance CorporationMAC - Part BMO
05402Wisconsin Physicians Service Insurance CorporationMAC - Part BNE
08101Wisconsin Physicians Service Insurance CorporationMAC - Part AIN
08102Wisconsin Physicians Service Insurance CorporationMAC - Part BIN
08201Wisconsin Physicians Service Insurance CorporationMAC - Part AMI
08202Wisconsin Physicians Service Insurance CorporationMAC - Part BMI
05901Wisconsin Physicians Service Insurance CorporationMAC - Part AAK AL AR AZ CA CO CT DE FL GA HI IA ID IL IN KS KY LA MA MD ME MI MO MS MT NC ND NE NH NJ NM NV OH OK OR PA RI SC SD TN TX UT VA VT WA WI WV WY

Billing and coding article A59551: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A59551 (Billing and Coding: MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

A59551: Billing and Coding: MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy (Billing and Coding, effective 2026-06-25)

Covered ICD-10-CM codes
2
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
1
Full article
cms.gov record
First 2 covered ICD-10-CM codes in A59551
ICD-10-CMDescription (FY2027)
R91.1Solitary pulmonary nodule
R91.8Other nonspecific abnormal finding of lung field

Procedure codes: 81479.

Coverage indications, limitations and medical necessity

This contractor will provide limited coverage for molecular tests to aid in the diagnosis or exclusion of lung cancer in a patient with an indeterminate pulmonary nodule (IPN) following a non-diagnostic bronchoscopy when ALL of the following conditions are met:

• The beneficiary has undergone bronchoscopy for an indeterminate pulmonary nodule AND

• The bronchoscopy has failed to provide a specific histopathological diagnosis such that further diagnostic procedures would otherwise be considered necessary to pursue a specific diagnosis (non-diagnostic bronchoscopy); AND

• Test results will be used to meaningfully inform patient management within the framework of nationally recognized consensus guidelines.

• The nodule cannot or will not be evaluated by an alternate methodology (EBUS, FNA, etc.) for a specific diagnosis prior to receipt of molecular test results.

• The beneficiary does NOT have any of the following:

• Personal history of lung cancer

• Current diagnosis of cancer or high clinical suspicion for cancer

• An overall low risk for pulmonary malignancy such that test results would not meaningfully alter patient management and significantly improve patient outcomes.

• An overall high risk for pulmonary malignancy such that test results would not meaningfully alter patient management and significantly improve patient outcomes.

• The beneficiary has not been tested with the same or similar assay for the same clinical indication.

• The beneficiary is within the population and has the indication for which the test was developed and is covered. The lab providing the test is responsible for clearly indicating to treating clinicians the population and indication for test use.

• The test has demonstrated clinical validity and utility, establishing a clear and significant biological/molecular basis for stratifying patients and subsequently selecting (either positively or negatively) a clinical management decision in a clearly defined population.

• Clinical validity of any analytes (or expression profiles) measured must be established through a study published in the peer-reviewed literature for the intended use of the test in the intended population.

• Rule-out tests should have high sensitivity and negative predictive value (NPV) such that patients can be safely selected for a less aggressive management strategy without delay to diagnosis due to false negative results.

• Rule-in tests should have high specificity and positive predictive value (PPV) such that patients can be safely selected for more aggressive management without significantly increasing procedures in patients without cancer due to false positive results.

• The test demonstrates analytical validity including both analytical and clinical validations. If the test relies on an algorithm (which may range in complexity from a threshold determination of a single numeric value to a complex mathematical or computational function), the algorithm must be validated in a cohort that is not a development cohort for the algorithm.

• Tests utilizing a similar methodology or evaluating a similar molecular analyte to a test for which there is a generally accepted testing standard or for which existing coverage exists must demonstrate equivalent or superior test performance (i.e., sensitivity and/or specificity) when used for the same indication in the same intended-use population. New tests that become available with significantly improved performance may render older tests no longer compliant with this policy.

• The test successfully completes a Molecular Diagnostic Services Program (MolDX®) technical assessment that ensures the test is reasonable and necessary as described above.

NOTE: Next Generation Sequencing (NGS) performed to identify genetic variants in samples classified as malignant is not within the scope of this policy but may fall under other established policies.

Summary of evidence (opening)

Lung Cancer Screening

Lung cancer is the leading cause of cancer-related deaths in the United States. 1 It is estimated that 236,740 new cases of lung and bronchial cancer will have been diagnosed in the United States in 2022 (117,910 in men and 118,830 in women) with 130,180 anticipated deaths (68,820 in men and 61,360 in women). 1 Earlier diagnosis has significant impact on clinical outcome, as 5-year survival increases from 6%-9.5% for distant-stage disease, to 33-44% for regional disease, and 60-75% for localized disease, 1 although there have been recent improvements in non-small cell lung cancer outcomes across stages with the advent of targeted and molecular therapies. 2 Data from larger randomized control trials such as the National Lung Screening Trial (NLST) and the Dutch-Belgian Randomized Lung Cancer Screening Trial (Nederlands–Leuvens Longkanker Screenings Onderzoek [NELSON]) supports low-dose CT (LDCT) screening in high-risk individuals based on smoking criteria and age. 3-5 A noticeable decline in advanced-stage lung cancer diagnosis with a corresponding increase in incidence of localized stage disease was observed between 2013 and 2018 following recommendation for lung cancer screening by the United States Preventive Services Task Force (USPSTF). 6 Due to increased strength of evidence supporting annual screening with LDCT for high-risk individuals, USPSTF issued updated screening guidelines in March of 2021, expanding eligibility to adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years. 6 The Centers for Medicare & Medicaid Services (CMS) covers annual LDCT screening for appropriate Medicare beneficiaries with significant smoking history up to 77 years of age if they participate in shared decision-making before their first screening LDCT. 7 LDCT screening is also recommended by the 2021 CHEST Guideline and Expert Panel Report on Screening for Lung Cancer. 8

Although there is consensus on the value of LDCT screening, uncertainty remains about the appropriate duration of screening and age of screening cessation, with NCCN recommending annual screening until the patient is no longer a candidate for definitive treatment. 9 There are also potential risks associated with LDCT screening including false negative as well as false positive results that can lead to unnecessary tests and invasive procedures, complications from the diagnostic workup, overdiagnosis of incidental findings, short-term anxiety due to indeterminate results, and radiation exposure. 9 As a result of increased implementation of screening guidelines, the incidence of nodules detected on CT continues to rise, and an estimated 1.5 million nodules are detected each year in the United States. 10 Most lung nodules found on LDCT are benign, 3,4 such that lung cancer prevalence in the screening setting is 0.8-2.2% and approximately 0.11% in nodules incidentally detected when imaging is performed for other reasons. 10 An LDCT screen is defined as “positive” if the size and morphologic features of the detected nodule results in a recommendation for follow-up testing in addition to recommended annual screening based on published guidelines. 8 Approximately 7% of patients with false positive results go on to an invasive procedure, most often bronchoscopy. 9,11,12

Indeterminate Pulmonary Nodules (IPN) Risk Assessment and Management Guidelines

The contractor cites 52 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2024-09-22
Current revision effective
2026-06-25
Last reviewed by the contractor
2026-05-27
MCD version
5

Other related documents: A59876 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Wisconsin Physicians Service Insurance Corporation hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L39711 cover?

• Rule-out tests should have high sensitivity and negative predictive value (NPV) such that patients can be safely selected for a less aggressive management strategy without delay to diagnosis due to false negative results. The full 577-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L39711 apply to?

Wisconsin Physicians Service Insurance Corporation applies it to Medicare claims in 48 states: AK, AL, AR, AZ, CA, CO, CT, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, WY. It binds only that contractor; 3 other contractor versions of this title govern other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L39711?

The companion billing and coding article A59551 lists 2 ICD-10-CM codes in 1 group that support medical necessity; the first 2 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L39711?

A denial under LCD L39711 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A59551's 2 covered diagnosis codes, then file a redetermination with Wisconsin Physicians Service Insurance Corporation within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.